Potential of paliperidone palmitate in long-term preventing therapy of relapses in schizophrenia (review of evidence-based studies)

Abstract

Nonadherence to medication in patients with schizophrenia is one of the main causes leading to an adverse outcome, while the use of prolonged forms of antipsychotics can significantly
increase patients’ compliance and, accordingly, significantly affect the overall effectiveness of long:term anti:relapse therapy. This review is devoted to the analysis of the results of randomized
clinical studies of two injection forms of paliperidone palmitate (monthly and three:month action). The scientific materials were obtained in the MEDLINE system as a result of a cross:
check of references found at the request of paliperidone palmitate in order to obtain the most relevant data, and concerned both placebo:controlled studies and studies with active control,
as well as retrospective observations. The considered compounds have been shown significantly superior to placebo and comparable with other modern antipsychotics efficiency, close to
risperidone safety profile, as well as a number of advantages related to the possibility of varying the frequency of injections and the lack of need for collateral assignment oral dosage forms.